Since 2022, the pharmaceutical industry has faced challenges due to the impact of the general environment, and in this context, multinational pharmaceutical companies have actively adjusted their structures and reduced personnel to reduce costs and focus more on developing core businesses
.
Recently, there are media reports that Zimmer Biomet (hereinafter referred to as Zimmer Bonme) is considering plans to transfer manufacturing to Costa Rica to achieve the purpose of
layoffs.
It is reported that the factory currently has 185 employees, and if the layoffs are implemented, only more than 30 people are expected to keep their jobs
.
Headquartered in Warsaw, Indiana, Zimmer Together with its subsidiaries, Zimmer Bangmei is principally engaged in the design, development, manufacture and sales of orthopedic reconstruction devices, spine and trauma devices, biologics, dental implants and related surgical products
in the Americas, Europe and Asia Pacific.
The analysis believes that the company's layoffs are mainly related to the decline in the company's sales revenue in recent years, and the company's revenue in 2020 is only 7.
025 billion US dollars, compared with 7.
98 billion US dollars in 2019, a decrease of 12%.
To this end, the company has made a number of spin-off initiatives, including Ellison (Ellie) M.
Humphrey, former vice president of business transformation of Medtronic, who will serve as chief transformation officer, and will spin off the spine and dental business, which will complete the merger and form a new independent public company (NewCo).
Under the business transformation, the company performed well in the third quarter of 2022, achieving a profit of US$194 million, a profit growth rate of 33.
2%, and sales of US$1.
67 billion, down 0.
9%.
Sales in the knee and hip businesses increased slightly, at 1.
4 percent and 3.
1 percent
, respectively.
At present, the company is still in the business transformation stage, and its key business layout in the third quarter includes the elimination of 80% of employees
.
It is reported that as early as November 2021, Zimmer Biomet laid off 65 employees at its headquarters in Warsaw to ease the pressure on the
company's business.
The relocation of the Ohio plant is also a layoff to divest some of its business
.
Since the beginning of this year, multinational biopharmaceutical companies that plan to cut jobs include Gilead Sciences, Eisai, Novartis, AbbVie, Bristol-Myers Squibb, oncoSec Medical, Oxford Biomedica, Finch Therapeutics, Palisade Bio and others
.
In terms of layoffs, Rubius Therapeutics, which in September, announced a strategic change in which it will cut 75% of its workforce, including clinical development, manufacturing, and general and administrative staff
.
For example, in October, OncoSec, a clinical-stage biotechnology company focused on developing intra-tumor immunotherapies, and Cyclerion Therapeutics, a clinical-stage biopharmaceutical company, both announced a 45% layoff in their jobs and shifted to their core business
.
The layoffs of many multinational companies are accompanied by the sale and closure of factories
.
In September, for example, Oxford Biomedica, a leading gene and cell therapy CDMO company, said it planned to cut jobs, sell and lease back its Oxford-based plant
to cut costs.
The company employs about 959 people, but hiring is currently frozen
.
Also in September, Novartis announced plans to close Sandoz generics in Wilson, North Carolina, which manufactures oral solid dosage products primarily for the U.
S.
and Canadian markets and employs about 246 people around the end of 2023, citing the inability to take full advantage of the U.
S.
facility
.
In early November, Novartis announced the closure of a gene therapy production site in Illinois, USA, eliminating nearly 300 jobs
.
From the perspective of the reasons for layoffs, factory sales, and closures, different pharmaceutical companies have made different reasons for taking relevant measures, some of which are for the sustainable development strategy of the enterprise, so as to adjust the marketing strategy; Some are a series of adjustments due to the failure of the drug development pipeline; Others are to "throttle", so as to streamline the business and invest in more core business
.
In general, under the change of market environment, pharmaceutical companies can only adapt to the environment and survive better if they continue to adjust
.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
